Arash Aryana1, David N Kenigsberg2, Marcin Kowalski3, Charles H Koo4, Hae W Lim5, Padraig Gearoid O'Neill6, Mark R Bowers6, Robert B Hokanson5, Kenneth A Ellenbogen7. 1. Mercy General Hospital and Dignity Health Heart and Vascular Institute, Sacramento, California. Electronic address: a_aryana@outlook.com. 2. Florida Heart Rhythm Specialists, PLLC, Plantation, Florida. 3. Staten Island University Hospital, Northwell Health, Staten Island, New York. 4. Jersey Shore University Medical Center, Neptune, New Jersey. 5. Medtronic, Inc, Minneapolis, Minnesota. 6. Mercy General Hospital and Dignity Health Heart and Vascular Institute, Sacramento, California. 7. Virginia Commonwealth University Medical Center, Richmond, Virginia.
Abstract
BACKGROUND: There are no recommendations on the optimal dosing for cryoablation of atrial fibrillation (Cryo-AF). OBJECTIVE: The purpose of this study was to develop and prospectively test a Cryo-AF dosing protocol guided exclusively by time-to-pulmonary vein (PV) isolation (TT-PVI) in patients undergoing a first-time Cryo-AF. METHODS: In this multicenter study, we examined the acute/long-term safety/efficacy of Cryo-AF using the proposed dosing algorithm (Cryo-AFDosing; n = 355) against a conventional, nonstandardized approach (Cryo-AFConventional; n = 400) in a nonrandomized fashion. RESULTS: Acute PV isolation was achieved in 98.9% of patients in Cryo-AFDosing (TT-PVI = 48 ± 16 seconds) vs 97.2% in Cryo-AFConventional (P = .18). Cryo-AFDosing was associated with shorter (149 ± 34 seconds vs 226 ± 46 seconds; P <.001) and fewer (1.7 ± 0.8 vs 2.9 ± 0.8; P <.001) cryoapplications, reduced overall ablation (16 ± 5 minutes vs 40 ± 14 minutes; P <.001), fluoroscopy time (13 ± 6 minutes vs 29 ± 13 minutes; P <.001), left atrial dwell time (51 ± 14 minutes vs 118 ± 25 minutes; P <.001), and total procedure time (84 ± 23 minutes vs 145 ± 49 minutes; P <.001) but similar nadir balloon temperature (-47°C ± 8°C vs -48°C ± 6°C; P = .41) and total thaw time (43 ± 27 seconds vs 45 ± 19 seconds; P = .09) as compared to Cryo-AFConventional. Adverse events (2.0% vs 2.7%; P = .48), including persistent phrenic nerve palsy (0.6% vs 1.2%; P = .33) and 12-month freedom from all atrial arrhythmias (82.5% vs 78.3%; P = .14), were similar between Cryo-AFDosing and Cryo-AFConventional. However, Cryo-AFDosing was specifically associated with fewer atypical atrial flutters/tachycardias during long-term follow-up (8.5% vs 13.5%; P = .02) as well as fewer late PV reconnections at redo procedures (5.0% vs 18.5%; P <.001). CONCLUSION: A novel Cryo-AF dosing algorithm guided by TT-PVI can help individualize the ablation strategy and yield improved procedural endpoints and efficiency as compared to a conventional, nonstandardized approach.
BACKGROUND: There are no recommendations on the optimal dosing for cryoablation of atrial fibrillation (Cryo-AF). OBJECTIVE: The purpose of this study was to develop and prospectively test a Cryo-AF dosing protocol guided exclusively by time-to-pulmonary vein (PV) isolation (TT-PVI) in patients undergoing a first-time Cryo-AF. METHODS: In this multicenter study, we examined the acute/long-term safety/efficacy of Cryo-AF using the proposed dosing algorithm (Cryo-AFDosing; n = 355) against a conventional, nonstandardized approach (Cryo-AFConventional; n = 400) in a nonrandomized fashion. RESULTS: Acute PV isolation was achieved in 98.9% of patients in Cryo-AFDosing (TT-PVI = 48 ± 16 seconds) vs 97.2% in Cryo-AFConventional (P = .18). Cryo-AFDosing was associated with shorter (149 ± 34 seconds vs 226 ± 46 seconds; P <.001) and fewer (1.7 ± 0.8 vs 2.9 ± 0.8; P <.001) cryoapplications, reduced overall ablation (16 ± 5 minutes vs 40 ± 14 minutes; P <.001), fluoroscopy time (13 ± 6 minutes vs 29 ± 13 minutes; P <.001), left atrial dwell time (51 ± 14 minutes vs 118 ± 25 minutes; P <.001), and total procedure time (84 ± 23 minutes vs 145 ± 49 minutes; P <.001) but similar nadir balloon temperature (-47°C ± 8°C vs -48°C ± 6°C; P = .41) and total thaw time (43 ± 27 seconds vs 45 ± 19 seconds; P = .09) as compared to Cryo-AFConventional. Adverse events (2.0% vs 2.7%; P = .48), including persistent phrenic nerve palsy (0.6% vs 1.2%; P = .33) and 12-month freedom from all atrial arrhythmias (82.5% vs 78.3%; P = .14), were similar between Cryo-AFDosing and Cryo-AFConventional. However, Cryo-AFDosing was specifically associated with fewer atypical atrial flutters/tachycardias during long-term follow-up (8.5% vs 13.5%; P = .02) as well as fewer late PV reconnections at redo procedures (5.0% vs 18.5%; P <.001). CONCLUSION: A novel Cryo-AF dosing algorithm guided by TT-PVI can help individualize the ablation strategy and yield improved procedural endpoints and efficiency as compared to a conventional, nonstandardized approach.
Authors: Valter Giaretto; Andrea Ballatore; Claudio Passerone; Paolo Desalvo; Mario Matta; Andrea Saglietto; Mario De Salve; Fiorenzo Gaita; Bruno Panella; Matteo Anselmino Journal: J R Soc Interface Date: 2019-09-18 Impact factor: 4.118
Authors: Julian Chun; Tilman Maurer; Andreas Rillig; Stefano Bordignon; Leon Iden; Sonia Busch; Daniel Steven; Roland R Tilz; Dong-In Shin; Heidi Estner; Felix Bourier; David Duncker; Philipp Sommer; Nils-Christian Ewertsen; Henning Jansen; Victoria Johnson; Livio Bertagnolli; Till Althoff; Andreas Metzner Journal: Herzschrittmacherther Elektrophysiol Date: 2021-11-04
Authors: Wilber Su; G Joseph Orme; Robert Hoyt; James Baker; Steven Compton; Christopher Fellows; John Harding; J Thomas Svinarich; Marcin Kowalski; Bryan Piedad; David Kenigsberg; John Seger; Zeshan K Ahmad; Paul Wang Journal: J Interv Card Electrophysiol Date: 2018-02-24 Impact factor: 1.900
Authors: Francesca Salghetti; Juan-Pablo Abugattas; Valentina De Regibus; Saverio Iacopino; Ken Takarada; Erwin Ströker; Hugo-Enrique Coutiño; Ian Lusoc; Juan Sieira; Lucio Capulzini; Giacomo Mugnai; Vincent Umbrain; Stefan Beckers; Pedro Brugada; Carlo de Asmundis; Gian-Battista Chierchia Journal: J Atr Fibrillation Date: 2018-04-30
Authors: Alexander Pott; Michael Baumhardt; Karolina Weinmann; Manuel Rattka; Tilman Stephan; Mirjam Keßler; Carlo Bothner; Kerstin Petscher; Wolfgang Rottbauer; Tillman Dahme Journal: Int J Cardiol Heart Vasc Date: 2019-04-30
Authors: Arash Aryana; Deep K Pujara; Shelley L Allen; James H Baker; Martin A Espinosa; Eric F Buch; Uma Srivatsa; Ethan Ellis; Kevin Makati; Marcin Kowalski; Sung Lee; Thomas Tadros; Tina Baykaner; Amin Al-Ahmad; André d'Avila; Luigi Di Biase; Kaoru Okishige; Andrea Natale Journal: J Interv Card Electrophysiol Date: 2020-10-03 Impact factor: 1.900